From my colleague Drew Joseph: Ahead of an advisory committee meeting Thursday focused on GSK’s multiple myeloma drug Blenrep, the FDA pointed to concerns about the high rates of eye issues that have ...

Briefing documents were disclosed relating to the meeting of the U.S. FDA’s Oncologic Drugs Advisory Committee (ODAC), which will convene July 17 on the matter of London-based GSK plc’s Blenrep ...

GSK (GSK) stock in focus as the FDA staff raise safety concerns over Blenrep combo for multiple myeloma ahead of an AdCom ...

Proposals by Robert F. Kennedy Jr. and Bernie Sanders range from more disclosures in commercials to an outright ban.

AnaptysBio’s lead drug rosnilimab showed promise in RA, but lack of a Phase 3 plan and limited pipeline raise concerns. Find ...

Glaxosmithkline, with multiple operations in Montco, just scored a major regulatory win that could reshape how lupus ...

U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline ...

Democratic U.S. Senator Maggie Hassan said on Friday she is launching an investigation into British pharmaceutical giant GlaxoSmithKline's decision to discontinue a widely used asthma inhaler for ...

Simply sign up to the Pharmaceuticals sector myFT Digest -- delivered directly to your inbox. GlaxoSmithKline will apply for approval for its respiratory syncytial virus vaccine for older adults ...

The Food and Drug Administration on Monday granted marketing approval to GlaxoSmithKline for Priorix, a vaccine to prevent measles, mumps and rubella in individuals a year or older.

As per the deal, GlaxoSmithKline will pay the vaccine maker up to $1.2 billion more if certain milestones are arrived at in Affinivax's impending clinical trials for a new pneumococcal vaccine.